The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000156.6(GAMT):c.59G>T (p.Trp20Leu)

CA402998326

588631 (ClinVar)

Gene: GAMT
Condition: guanidinoacetate methyltransferase deficiency
Inheritance Mode: Autosomal recessive inheritance
UUID: c9c80575-0e97-4d8a-bd94-486ed947d032

HGVS expressions

NM_000156.6:c.59G>T
NM_000156.6(GAMT):c.59G>T (p.Trp20Leu)
NC_000019.10:g.1401418C>A
CM000681.2:g.1401418C>A
NC_000019.9:g.1401417C>A
CM000681.1:g.1401417C>A
NC_000019.8:g.1352417C>A
NG_009785.1:g.5136G>T
ENST00000252288.8:c.59G>T
ENST00000447102.8:c.59G>T
ENST00000640762.1:c.59G>T
ENST00000252288.6:c.59G>T
ENST00000447102.7:c.59G>T
NM_000156.5:c.59G>T
NM_138924.2:c.59G>T
NM_138924.3:c.59G>T

Uncertain Significance

Met criteria codes 3
PP3 PM5 PM2_Supporting

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GAMT Version 1.1.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Cerebral Creatine Deficiency Syndromes VCEP
The NM_000156.6:c.59G>T variant in GAMT is a missense variant that is predicted to result in the substitution of tryptophan by leucine at amino acid 20 (p.Trp20Leu). To our knowledge, this variant has not been reported in individuals with GAMT deficiency and the result of functional studies are not available. The computational predictor REVEL gives a score of 0.804 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3). Another missense variant, c.59G>C (p.Trp20Ser) (ClinVar Variation ID: 8303)) has been reported at the same amino acid position and has been classified as pathogenic for GAMT deficiency by the ClinGen CCDS VCEP (PM5). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 588631, 1 star review status). In summary, this variant meets the criteria to be classified as uncertain significance for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PM2_Supporting, PM5, PP3. (Classification approved by the ClinGen CCDS VCEP, Sept 12, 2023)
Met criteria codes
PP3
The computational predictor REVEL gives a score of 0.804 which is above the threshold of 0.75, evidence that correlates with impact to GAMT function (PP3).
PM5
Other missense variants at the same amino acid residue have been reported pathogenic (Trp20Ser - ClinVar ID 8303, Pathogenic)
PM2_Supporting
Absent in gnomAD v2.1.1 (PM2_Supporting).
Approved on: 2023-09-13
Published on: 2023-09-13
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.